Abstract:Background Accurately assessing 5‐year recurrence rates is crucial for managing non‐muscle‐invasive bladder carcinoma (NMIBC). However, the European Organization for Research and Treatment of Cancer (EORTC) model exhibits poor performance. Purpose To investigate whether integrating multiparametric MRI (mp‐MRI) with clinical factors improves NMIBC 5‐year recurrence risk assessment. Study Type Retrospective. Population One hundred ninety‐one patients (median age, 65 years; age range, 54–73 years; 27 females) underwent mp‐MRI between 2011 and 2017, and received ≥5‐year follow‐ups. They were divided into a training cohort (N = 115) and validation/testing cohorts (N = 38 in each). Recurrence rates were 23.5% (27/115) in the training cohort and 23.7% (9/38) in both validation and testing cohorts. Field Strength/Sequence 3‐T, fast spin echo T2‐weighted imaging (T2WI), single‐shot echo planar diffusion‐weighted imaging (DWI), and volumetric spoiled gradient echo dynamic contrast‐enhanced (DCE) sequences. Assessment Radiomics and deep learning (DL) features were extracted from the combined region of interest (cROI) including intratumoral and peritumoral areas on mp‐MRI. Four models were developed, including clinical, cROI‐based radiomics, DL, and clinical‐radiomics‐DL (CRDL) models. Statistical Tests Student's t‐tests, DeLong's tests with Bonferroni correction, receiver operating characteristics with the area under the curves (AUCs), Cox proportional hazard analyses, Kaplan–Meier plots, SHapley Additive ExPlanations (SHAP) values, and Akaike information criterion for clinical usefulness. A P‐value <0.05 was considered statistically significant. Results The cROI‐based CRDL model showed superior performance (AUC 0.909; 95% CI: 0.792–0.985) compared to other models in the testing cohort for assessing 5‐year recurrence in NMIBC. It achieved the highest Harrell's concordance index (0.804; 95% CI: 0.749–0.859) for estimating recurrence‐free survival. SHAP analysis further highlighted the substantial role (22%) of the radiomics features in NMIBC recurrence assessment. Data Conclusion Integrating cROI‐based radiomics and DL features from preoperative mp‐MRI with clinical factors could improve 5‐year recurrence risk assessment in NMIBC. Evidence Level 3 Technical Efficacy Stage 3

Deep Learning-Based PET/MR Radiomics for the Classification of Annualized Relapse Rate in Multiple Sclerosis

Joint Radiomics and Spatial Distribution Model for MRI-based Discrimination of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin-Oligodendrocyte-glycoprotein-igg-associated Disorder.

An Automated Hybrid Approach Via Deep Learning and Radiomics Focused on the Midbrain and Substantia Nigra to Detect Early-Stage Parkinson’s Disease

Prediction of unenhanced lesion evolution in multiple sclerosis using radiomics-based models: a machine learning approach

Multi-lesion radiomics model for discrimination of relapsing-remitting multiple sclerosis and neuropsychiatric systemic lupus erythematosus

Interpretable and Intuitive Machine Learning Approaches for Predicting Disability Progression in Relapsing-Remitting Multiple Sclerosis Based on Clinical and Gray Matter Atrophy Indicators

Predicting PET-derived myelin content from multisequence MRI for individual longitudinal analysis in multiple sclerosis

Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder

Multi-parametric MRI Phenotype with Trustworthy Machine Learning for Differentiating CNS Demyelinating Diseases

Multiparametric MRI‐Based Deep Learning Radiomics Model for Assessing 5‐Year Recurrence Risk in Non‐Muscle Invasive Bladder Cancer

Discriminating Minimal Residual Disease Status in Multiple Myeloma Based on MRI: Utility of Radiomics and Comparison of Machine-Learning Methods.

Interpretable deep learning as a means for decrypting disease signature in multiple sclerosis

Automated Prediction of Early Recurrence in Advanced Sinonasal Squamous Cell Carcinoma with Deep Learning and Multi-parametric MRI-based Radiomics Nomogram.

Predicting multiple sclerosis disease severity with multimodal deep neural networks

18F-Florbetapir PET/MRI for Quantitatively Monitoring Myelin Loss and Recovery in Patients with Multiple Sclerosis: A Longitudinal Study.

Predicting PET-derived Demyelination from Multimodal MRI Using Sketcher-Refiner Adversarial Training for Multiple Sclerosis.

MRI-Based Machine Learning for Prediction of Clinical Outcomes in Primary Central Nervous System Lymphoma

Deep Learning with Diffusion Basis Spectrum Imaging for Classification of Multiple Sclerosis Lesions

Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis

Temporally Adjustable Longitudinal Fluid-Attenuated Inversion Recovery MRI Estimation / Synthesis for Multiple Sclerosis

Multimodal radiomics-based methods using deep learning for prediction of brain metastasis in non-small cell lung cancer with 18F-FDG PET/CT images